Published in Am J Pathol on March 26, 2009
SOCS, inflammation, and cancer. JAKSTAT (2013) 1.13
Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget (2012) 1.11
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res (2011) 0.95
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer (2014) 0.89
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol (2014) 0.87
Hepatocyte proliferation/growth arrest balance in the liver of mice during E. multilocularis infection: a coordinated 3-stage course. PLoS One (2012) 0.86
Role of SOCS-1 Gene on Melanoma Cell Growth and Tumor Development. Transl Oncol (2011) 0.83
The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol (2015) 0.82
Molecular signaling involving intrinsically disordered proteins in prostate cancer. Asian J Androl (2016) 0.77
15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells. PPAR Res (2016) 0.76
Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer (2017) 0.75
Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment. Front Immunol (2017) 0.75
[Diagnostic of prostate cancer: conventional and molecular or cell biological methods]. Pathologe (2009) 0.75
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol (2001) 1.86
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology (1995) 1.62
Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res (2002) 1.57
IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol (2007) 1.55
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene (2005) 1.55
PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate (2006) 1.55
Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther (2006) 1.54
Suppressors of cytokine signalling: SOCS. APMIS (2002) 1.33
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis (2008) 1.32
The tumor suppressor activity of SOCS-1. Oncogene (2002) 1.29
A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene (2005) 1.24
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut (2007) 1.22
STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate (2000) 1.19
Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer (2008) 1.17
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A (2008) 1.17
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res (2008) 1.14
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun (2007) 1.11
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol (2004) 1.11
Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res (2007) 1.09
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate (2007) 1.06
Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther (2006) 1.05
SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res (2007) 1.04
Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer (2004) 1.03
Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res (2007) 1.02
Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate (2008) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia (2006) 0.99
Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways. Diabetologia (2004) 0.98
Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol (2003) 0.96
Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer (2005) 0.95
Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology (2004) 0.94
Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene (2003) 0.93
The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica (2004) 0.93
Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J (2007) 0.91
The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am J Hematol (2007) 0.91
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer (2007) 0.89
Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells. Biochem Biophys Res Commun (2005) 0.88
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A (2010) 2.72
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell (2009) 2.57
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol (2006) 2.29
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Derivation of nephrogenic adenomas from renal tubular cells in kidney-transplant recipients. N Engl J Med (2002) 1.69
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology (2007) 1.67
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol (2004) 1.65
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer (2008) 1.48
The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J (2004) 1.46
Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes (2010) 1.44
Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J (2012) 1.43
Translational regulation mechanisms of AP-1 proteins. Mutat Res (2009) 1.42
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol (2011) 1.41
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther (2011) 1.39
c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol (2005) 1.39
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
Spindly/CCDC99 is required for efficient chromosome congression and mitotic checkpoint regulation. Mol Biol Cell (2010) 1.33
Cardiopulmonary resuscitation-associated major liver injury. Resuscitation (2007) 1.33
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells (2012) 1.19
[The first autochthonous case of subcutaneous dirofilariosis in Austria]. Wien Klin Wochenschr (2008) 1.18
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood (2007) 1.18
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology (2010) 1.17
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle (2011) 1.17
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A (2008) 1.17
Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol (2012) 1.16
Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta (2008) 1.16
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer (2010) 1.16
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A (2010) 1.15
Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int (2007) 1.15
Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology (2003) 1.14
Loss of the mammalian APC/C activator FZR1 shortens G1 and lengthens S phase but has little effect on exit from mitosis. J Cell Sci (2009) 1.13
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Mol Cell Biol (2011) 1.12
Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol (2005) 1.12
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
Human chromokinesins promote chromosome congression and spindle microtubule dynamics during mitosis. J Cell Biol (2012) 1.10
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res (2009) 1.09
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
Androgen receptors in prostate cancer. J Urol (2003) 1.07
A novel approach to energy ablative therapy of small renal tumours: laparoscopic high-intensity focused ultrasound. Eur Urol (2007) 1.07
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med (2013) 1.07
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 1.06
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06
Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol (2005) 1.05
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Occurrence of polyorchidism in a young man. Urology (2002) 1.05
JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J (2004) 1.04
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J (2010) 1.03
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol (2008) 1.01
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology (2010) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Histone acetyl transferase 1 is essential for mammalian development, genome stability, and the processing of newly synthesized histones H3 and H4. PLoS Genet (2013) 0.99
'Skipping' is still a problem with radiofrequency ablation of small renal tumours. BJU Int (2007) 0.99
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther (2009) 0.98
Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol (2002) 0.98
Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation--a new paradigm for cooperation among prostate tumor cells. Int J Cancer (2007) 0.98
Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology (2004) 0.97
Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology (2012) 0.97